Daily Brief Health Care: HealthCare Global Enterprises, Acrobiosystems, Vsee Health, Divi’s Laboratories and more

• CVC Capital Partners fully exited Healthcare Global (HCG) in mid-2025, selling its 54% stake to KKR at ₹445 per share. Post-acquisition, KKR has pushed a pure-play oncology strategy, highlighted by the June 2026 divestment of the loss-making Milann fertility business for ₹37.64 crore equity value.
• The Supreme Court’s September 29, 2026 proposal for a 16% retail markup cap on oncology drugs is the most material near-term threat to EBITDA. Because medical oncology represents 38% of HCG’s specialty mix, a hard cap would severely compress pharmacy margins. HCG’s primary defensive levers include restructuring and bundling procedural billing packages and inflating unregulated bed, diagnostic, and radiation charges.
• Under KKR’s sole control, the governance structure has shifted entirely to professional management led by ED and CEO Dr. Manish Mattoo. While founder Dr. B.S. Ajaikumar remains as Non-Executive Chairman, day-to-day operations and capital allocation are tightly managed under KKR’s institutional framework, targeting a ramp-up to 21-22% EBITDA margins in the next two years.

• Defensive Dual-Listing Dynamics: Acrobiosystems’ resubmission of its H-share listing application on September 30, 2026, represents a defensive capital play to hedge against geopolitical fragmentation, establish a currency bridge for overseas M&A, and tap into offshore liquidity as its high-cost global footprint expands.
• Product Mix Drives Margin Compression: While core recombinant proteins maintain elite structural gross margins (91.15% in 1H26), consolidated gross margins have compressed to 83.07% TTM. This dilution is structurally driven by a deliberate mix shift toward lower-margin assay kits and technical services, coupled with localized GMP warehouse logistics.
• Divergent Growth Recovery: Despite a seemingly robust 31.43% YoY revenue expansion in 2Q26 to RMB 264.01 million, underlying recurring operational profitability remains weak (ex-nonrecurring net profit fell 5.3% YoY). This divergence highlights high overhead, localized commercialization costs, and massive share-based compensation overhead (RMB 12 million in 2Q26 alone).

• VSee Health, Inc., through its subsidiary iDoc, provides high acuity patient care solutions, specifically specialty intensive care unit services, aiming to bridge care gaps.
• VSee Health provides high acuity patient care solutions through iDoc, serving diverse customers from hospital systems to the federal prison system.
• The company reported operating losses and an accumulated deficit, with substantial doubt about its ability to continue as a going concern.

This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.

• NIFTY 50 represents the 50 largest stocks listed in the National Stock Exchange (NSE) of India and the NIFTY Next 50 index tracks the next 50 largest names.
• Here we have presented our expectations for these indices for the upcoming index rebal event in March 2027.
• We see two changes for NIFTY 50 and five changes for NIFTY 100.